

Medicare Intermediary Manual Part 3 - Claims Process

Department of Health and
Human Services (DHHS)
HEALTH CARE FINANCING
ADMINISTRATION (HCFA)

Transmittal 1818

Date: DECEMBER 19, 2000

CHANGE REQUEST 1198

<u>HEADER SECTION NUMBERS</u>	<u>PAGES TO INSERT</u>	<u>PAGES TO DELETE</u>
Table of Contents - Chapter VII 3660.16	6-5 - 6-6 (2 pp.) 6-344.6E (1 p.)	6-5 - 6-6 (2 pp.) 6-344.6E (1 p.)

NEW/REVISED MATERIAL--EFFECTIVE DATE: March 1, 1997
IMPLEMENTATION DATE: April 1, 2001

Section 3660.15, Oral Anti-Nausea Drugs as Full Therapeutic Replacements for Intravenous Dosage Forms As Part of a Cancer Chemotherapeutic Regimen, updates this section to reflect the revenue code Home Health Agencies (HHAs) are to report when billing for chemotherapy drugs, when necessary for the effective use of durable medical equipment (DME) as defined in ' 3629.F.9. HHAs report the drug HCPCS code under revenue code 294, however, the Common Working File (CWF) edit was not updated to accept this revenue code in this situation. As a result, CWF will change its editing to allow these drug HCPCS codes to be reported under revenue code 294 for HHAs.

If you receive claims from HHAs containing chemotherapy HCPCS codes reported under 294, suspend and hold them in your internal system. You may release them for payment April 1, 2001 after the necessary systems modifications have been made. At that time, you must pay any applicable interest. Interest is payable on "clean" claims not paid timely in accordance with the claims processing timeliness guidelines in §36600.1.

Do not search for previously adjudicated claims. However, reopen and reprocess claims brought to your attention.

These instructions should be implemented within your current operating budget.

DISCLAIMER: The revision date and transmittal number only apply to the redlined material. All other material was previously published in the manual and is only being reprinted.

CHAPTER VII
BILL REVIEW

	<u>Section</u>
Adjustments of Episode Payment--Partial Episode Payment (PEP).....	3639.28
Adjustments of Episode Payment--Significant Change in Condition (SCIC).....	3639.29
Adjustments of Episode Payment--Outlier Payments.....	3639.30
Adjustments of Episode Payment--Exclusivity and Multiplicity of Adjustments.....	3639.31
Exhibit: Seven Scenarios for Home Health Prospective Payment Adjustment.....	3639.32
Exhibit: General Guidance on Line Item Billing Under HH PPS	3639.33
Exhibit: Acronym Table.....	3639.34
Home Health Prospective Payment System (HH PPS) Consolidated Billing and Primary HHAs.....	3639.35
New Common Working File (CWF) Requirements for the Home Health Prospective Payment System (HH PPS).....	3640
Creation of the Health Insurance Query System for Home Health Agencies (HIQH) and Hospices in the Common Working File--Replacement of HIQA.....	3640.1
HIQH Inquiry and Response.....	3640.2
Timeliness and Limitations of HIQH Responses.....	3640.3
Inquiries to Regional Home Health Intermediaries (RHHIs) Based on HIQH Responses.....	3640.4
National Home Health Prospective Payment Episode History File.....	3640.5
Opening and Length of HH PPS Episodes	3640.6
Closing, Adjusting and Prioritizing HH PPS Episodes Based on RAP and HHA Claim Activity.....	3640.7
Other Editing and Changes for HH PPS Episodes.....	3640.8
Priority Among Other Claim Types and HH PPS Consolidating Billing for Episodes.....	3640.9
Medicare Secondary Payment (MSP) and the HH PPS Episode File.....	3640.10
Exhibit: Chart Summarizing Effects of RAP/Claim Actions on the HH PPS Episode File.....	3640.11
Rural Health Clinics - General.....	3642
Federally Qualified Health Centers.....	3643
Dialysis for ESRD - General.....	3644
Special Consideration When Processing ESRD Bills Under Method I.....	3644.1
Review of ESRD Bills Under Method I.....	3644.2
Special Consideration When Processing ESRD Bills Under Method II.....	3644.3
Processing the HCFA-382, ESRD Beneficiary Selection.....	3644.4
Coding for Adequacy of Hemodialysis.....	3644.5
Review of Hospice Bills	3648
Clarifications of Reimbursement for Transfers That Result in Same Day Hospice Discharge and Admission.....	3648.1
Comprehensive Outpatient Rehabilitation Facilities (CORFS).....	3650
Bill Review For Partial Hospitalization Services Provided In Community Mental Health Centers (CMHCs).....	3651
Billing for Abortion Services.....	3652

Physician Services

Coordination With Health Maintenance Organizations.....	3654
Provider Billing for Services Provided to HMO Beneficiaries	3654.1
Patient Is a Member of HMO for Only Part of Billing Period.....	3654.2
Computer Programs Supplied by HCFA	3656
Medicare Code Editor (MCE).....	3656.1
DRG Grouper Program.....	3656.2
PPS Pricer Program.....	3656.3
Ambulatory Surgical Center (ASC) Pricer Program.....	3656.4
Outpatient Code Editor (OCE).....	6-5

CHAPTER VII
BILL REVIEW

	<u>Section</u>
Radiology Pricer Program.....	3656.6
Home Health Prospective Payment System (HH PPS) Pricer Program	3656.7
Special Billing Situations.....	3660
Ambulance Services.....	3660.1
All-Inclusive Rate Providers.....	3660.4
Hospitals That Do Not Charge.....	3660.5
Billing for Parenteral and Enteral Nutrition (PEN).....	3660.6
Pneumococcal Pneumonia, Influenza Virus and Hepatitis B Vaccines.....	3660.7
Immunosuppressive Drugs Furnished to Transplant Patients.....	3660.8
Payment for CRNA or AA Services.....	3660.9
Mammography Screening.....	3660.10
Self-Administered Drugs and Biologicals.....	3660.11
Self-Administered Drug Administered in an Emergency Situation.....	3660.12
Oral Cancer Drugs	3660.13
Self-Administered Anti-emetic Drugs	3660.14
Oral Anti-Nausea Drugs as Full Therapeutic Replacements for Intravenous Dosage Forms as Part of a Cancer Chemotherapeutic Regimen.....	3660.15
Mammography Quality Standards Act (MQSA).....	3660.16
Colorectal Screening.....	3660.17
Extracorporeal Immunoabsorption (ECI) Using Protein A Columns.....	3660.18
Hospital Outpatient Partial Hospitalization Services.....	3661
Billing for Hospital Outpatient Services Furnished by Clinical Social Workers (CSWs).....	3662
Outpatient Observation Services.....	3663
Adjustment Bills.....	3664
Tolerance Guides for Submitting Adjustment Bills.....	3664.1
Physician Services.....	3668
Billing for Physicians Services	3668.1
Combined Billing by All-Inclusive Rate and Teaching Hospitals.....	3668.2

Cost Reimbursement Providers

Residents and Interns Not Under Approved Teaching Programs	3669
Detection of Duplicate Claims.....	3670
Coordination with Carriers.....	3672
Part A Denials	3672.1
Nonphysician Services Furnished to Hospital Inpatients Are Billed to Carrier.....	3672.2
Corrective Action When Nonphysician Services Are Furnished to Hospital Inpatients.....	3672.3
Recovery of Overpayment When Nonphysician Services Furnished to Hospital Inpatient Paid by Carrier.....	3672.4
Format and Content of A/B Data Match Record Furnished by Carrier.....	3672.5
Format for Fee Schedule, Prevailing Charge and Conversion Factor Data.....	3672.6
Coordination with the PRO.....	3674
Limitation of Liability Provision.....	3674.1
General Responsibilities of Hospitals, PROs, and Intermediaries.....	3674.2
PRO Preadmission/Preprocedure Review.....	3674.3
PRO Prepayment Review System (PRS).....	3674.4
PRO Reporting on Medical Review	3674.5

- Q0176 PERPHENAZINE, 8 mg, oral, FDA approved prescription anti-emetic, for use as a complete therapeutic substitute for an IV anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hours dosage regimen.
- Q0177 HYDROXYZINE PAMOATE, 25 mg, oral, FDA approved prescription anti-emetic, for use as a complete therapeutic substitute for an IV anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen.
- Q0178 HYDROXYZINE PAMOATE, 50 mg, oral, FDA approved prescription anti-emetic, for use as a complete therapeutic substitute for an IV anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen.
- Q0179 ONDANSETRON HYDROCHLORIDE, 8 mg, oral, FDA approved prescription anti-emetic, for use as a complete therapeutic substitute for an IV anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen.
- Q0180 DOLASETRON MESYLATE, 100 mg, oral, FDA approved prescription anti-emetic, for use as a complete therapeutic substitute for an IV anti-emetic at the time of chemotherapy treatment, not to exceed a 24 hour dosage regimen.
- Q0181 UNSPECIFIED ORAL DOSAGE FORM, FDA approved prescription anti-emetic, for use as a complete therapeutic substitute for a IV anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen.

NOTE: The 24 hour maximum drug supply limitation on dispensing, for HCPCS codes Q0166 and Q0180, has been established to bring the Medicare benefit as it applies to these two therapeutic entities in conformity with the Indications and Usage@ section of currently Food and Drug Administration approved product labeling for each affected drug product.

In addition, when billing for chemotherapy drugs (which includes oral cancer and IV chemotherapy drugs), providers must report the HCPCS code of the chemotherapy drug in FL 44 under revenue code 636 in FL 42, except for HHAs (bill types 32X, 33X, and 34X). HHAs coverage of these drugs is under the DME benefit, when necessary, for the effective use of DME as defined in ' 3629.F.9. HHAs report the drug HCPCS code under revenue code 294.

NOTE: When billing for an oral anti-emetic drug(s) and the provider is utilizing the hard copy UB-92 (Form HCFA-1450), the provider must report the name of the oral anti-emetic drug(s) in FL 43 ADescription@ on the appropriate revenue lines.

B. Line Item Dates of Service Reporting.--When billing for an oral anti-emetic drug(s) used as full replacement for intravenous forms, providers are required to report line item dates of service for the oral anti-emetic(s). Line item dates of service are reported in FL 45 AService Date@ (MMDDYYYY). (See example below.)

C. Service Unit Reporting.--Providers are required to report the number of units of the oral anti-emetic drug(s) in FL 46 AService Units@ for each drug reported. Each HCPCS code descriptor is equal to one service unit.

Providers complete the remaining items in accordance with regular billing instructions.

3660.16 Mammography Quality Standards Act (MQSA).--The MQSA requires the Secretary to ensure that all facilities that provide mammography services meet national quality standards.

The next page is 6-344.6G.